ERBB2 and breast carcinoma: We found that the combination treatment of pyrotinib and chrysin dampened the G6PD expression in HER2-positive breast cancer cells, whereas overexpression of miR-16-5p or knockdown of ZBTB16 increased the G6PD expression in breast cancer cells, along with apparently decreased autophagy.